| ALX Oncology's Evorpacept Gains Momentum With FDA Fast Track Designations | 09/11 22:36 | seekingalpha.com |
| ALX Oncology Appoints Alan Sandler, M.D., to Board of Directors | 08/06 16:01 | globenewswire.com |
| ALX Oncology Reports Topline Data From ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Improves Tumor Response in Patients With HER2-Positive Gastric Cancer | 07/31 16:01 | globenewswire.com |
| ALX Oncology to Host Investor Call and Webcast to Share Topline Data Results From ASPEN-06 Phase 2 Clinical Trial of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer | 07/31 05:30 | globenewswire.com |
| ALX Oncology: Finally Reaching A Reasonable Buy-In Valuation | 06/27 04:13 | seekingalpha.com |
| Down -30.79% in 4 Weeks, Here's Why ALX Oncology Holdings (ALXO) Looks Ripe for a Turnaround | 06/03 10:36 | zacks.com |
| ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder Cancer | 06/02 10:00 | globenewswire.com |
| ALX Oncology Announces Participation in the Jefferies Global Healthcare Conference | 05/29 09:00 | globenewswire.com |
| Wall Street Analysts Think ALX Oncology Holdings (ALXO) Could Surge 36.64%: Read This Before Placing a Bet | 05/14 10:56 | zacks.com |
| ALX Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update | 05/09 16:00 | globenewswire.com |